Published in Cancer Weekly, January 16th, 2007
ThinkEquity Partners LLC acted as lead placement agent and Rodman & Renshaw, LLC acted as co-placement agent in connection with this transaction. Continuing and new institutional investors participated in the transaction, including Celgene Corporation, EntreMed's principal shareholder.
James S. Burns, EntreMed president and chief executive officer, commented,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.